E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma.
	    		
		   		
		   			
		   		
	    	
    	- Author:
	        		
		        		
		        		
			        		Youn Jin CHOI
			        		
			        		
			        		
			        			1
			        			
			        		
			        		
			        		
			        		
			        		;
		        		
		        		
		        		
			        		Ahwon LEE
			        		
			        		;
		        		
		        		
		        		
			        		Tae Jung KIM
			        		
			        		;
		        		
		        		
		        		
			        		Hyun Tak JIN
			        		
			        		;
		        		
		        		
		        		
			        		Yong Bok SEO
			        		
			        		;
		        		
		        		
		        		
			        		Jong Sup PARK
			        		
			        		;
		        		
		        		
		        		
			        		Sung Jong LEE
			        		
			        		
		        		
		        		
		        		
			        		
			        		Author Information
			        		
 - Publication Type:Original Article
 - Keywords: Cervical Intraepithelial Neoplasia; Uterine Cervical Neoplasms; Human Papillomavirus Type 16 L1 Protein; Immunocytochemistry; Viral Integration
 - MeSH: Area Under Curve; Biomarkers*; Capsid Proteins; Carcinoma, Squamous Cell*; Cervical Intraepithelial Neoplasia; Epithelial Cells*; Genotype; Humans; Immunochemistry; Immunohistochemistry; Outpatients; ROC Curve; Squamous Intraepithelial Lesions of the Cervix*; Uterine Cervical Neoplasms; Virus Integration
 - From:Journal of Gynecologic Oncology 2018;29(3):e38-
 - CountryRepublic of Korea
 - Language:English
 - Abstract: OBJECTIVE: Human papillomavirus (HPV) 16 is the most carcinogenic HPV genotype. We investigated if HPV16 L1 capsid protein and E2/E6 ratio, evaluated by cervical cytology, may be used as biomarkers of ≥cervical intraepithelial neoplasia (CIN) 2 lesions. METHODS: Cervical specimens were obtained from 226 patients with HPV16 single infection. Using cytology specimen, L1 capsid protein and E2/E6 ratio were detected and the results were compared with those of the conventional histologic analysis of cervical tissues (CIN1–3 and squamous cell carcinoma [SCC]) to evaluate the association. RESULTS: The L1 positivity of CIN2/3 was significantly lower than that of normal cervical tissue (p < 0.001) and SCC demonstrated significantly lower L1 positivity than CIN1 (p < 0.001). The mean E2/E6 ratios of specimens graded as SCC (0.356) and CIN2/3 (0.483) were significantly lower than those of specimens graded as CIN1 (0.786) and normal (0.793) (p < 0.05). We observed that area under the receiver operating characteristic curve (AUC) for E2/E6 ratio (0.844; 95% confidence interval [CI]=0.793–0.895) was higher than that for L1 immunochemistry (0.636; 95% CI=0.562–0.711). A combination of E2/E6 ratio and L1 immunocytochemistry analyses showed the highest AUC (0.871; 95% CI=0.826–0.917) for the prediction of ≥CIN2 lesions. CONCLUSION: To our knowledge, this is the first study to validate HPV L1 capsid protein expression and decreased HPV E2/E6 ratio as valuable predictive markers of ≥CIN2 cervical lesions. Cervical cytology may be analyzed longitudinally on an outpatient basis with noninvasive procedures as against invasive conventional histologic analysis.
 
            